Core Viewpoint - The company has approved the use of its own funds and bank acceptance bills to pay for fundraising projects, with plans to replace these with raised funds later, ensuring the normal implementation of fundraising projects [1][6][7] Summary of Fundraising Situation - The company raised a total of RMB 839.4 million by issuing 60 million shares at RMB 13.99 per share, with total issuance costs amounting to RMB 79.83 million [1][2] - The funds were fully received by July 13, 2020, and have been managed in a dedicated account as per regulatory requirements [1][2] Summary of Investment Projects - As of June 30, 2025, the raw material drug production R&D project has been completed, while other fundraising projects are ongoing [2][3] - Specific projects include the Phase III clinical project for Aibond (艾诺韦林片) and the ACC008 project, with total investments of RMB 53.22 million and RMB 38.60 million respectively [3][4] Reasons for Using Own Funds - The company has used its own funds and bank acceptance bills for several reasons, including the need to pay employee salaries and taxes, which cannot be paid directly from the fundraising account [4][5] - Additionally, payments for overseas equipment and services require foreign currency, which cannot be processed through the fundraising account [4][5] Operational Process for Fund Replacement - The company will regularly compile a detailed list of payments made with its own funds and bank acceptance bills, which will be approved by the financial department [5][6] - After approval, equivalent amounts will be transferred from the fundraising account to replace the funds used [5][6] Impact on Daily Operations - The use of own funds and bank acceptance bills is expected to enhance the efficiency of fund utilization without affecting the normal operation of fundraising projects or the company's daily business [6][7] Review Procedures - The board and supervisory committee have approved the proposal to use own funds and bank acceptance bills, which does not require shareholder approval [6][7] - The proposal aligns with regulatory requirements and does not alter the intended use of the raised funds [6][7]

Group 1 - The company is proposing a stock option incentive plan for 2025 to attract and retain talent, aligning the interests of shareholders, the company, and core team members [5][6][8] - The stock option incentive plan has been approved by the company's board and supervisory committee and is now submitted for shareholder approval [6][8] - The company will conduct the shareholder meeting on July 14, 2025, with both on-site and online voting options available [5][7] Group 2 - The company plans to change its name from "Jiangsu Aidea Pharmaceutical Co., Ltd." to "Jiangsu Aidea Pharmaceutical Group Co., Ltd." to enhance group management and resource utilization [12][13] - The name change aligns with the company's strategic development needs and will not adversely affect its operations or shareholder interests [13][14] - The company will also revise its articles of association to reflect the name change and will seek necessary approvals for the changes [14][22] Group 3 - The company intends to adjust its fundraising investment projects, specifically changing the focus from "Ustectidine New Indication Research Project" to "Integrase Inhibitor Drug Research and Clinical Study Project" [16][19] - The total amount of funds to be redirected is approximately 84.37 million yuan, which will be fully allocated to the new project [15][19] - The integrase inhibitor project aims to develop a new generation of anti-HIV drugs and has shown promising results in initial clinical trials [20][21] Group 4 - The company is proposing the appointment of a new independent director candidate, Hu Wenyuan, following the resignation of the previous independent director [11][12] - The nomination has been approved by the board and is now subject to shareholder approval [11][12] - The company is also seeking to fill a vacancy in the supervisory board due to the resignation of a non-employee representative supervisor [22][23]

Core Viewpoint - Jiangsu Aidi Pharmaceutical Co., Ltd. is adjusting its fundraising investment projects to enhance the efficiency of fund usage and expedite the development of advantageous projects, specifically by reallocating funds from the "Ustectidine New Indication Research Project" to the "Integrase Inhibitor Drug Research and Clinical Study Project" [4][8][14] Fundraising Investment Project Overview - As of June 20, 2025, the raw material drug production research and supporting facilities project has been completed, while other fundraising projects are ongoing [2] - The total amount of committed investment for the projects is 542.8 million yuan, with 396.6 million yuan invested by June 20, 2025 [3] Changes and Amount Adjustments - The company plans to change the name of the project "Ustectidine New Indication Research Project" to "Integrase Inhibitor Drug Research and Clinical Study Project" and adjust the investment amounts accordingly [4][5] - The remaining funds of 84.3699 million yuan from the original project will be fully allocated to the new project to meet its funding needs [6][9] Reasons for Changes - The original project faced delays due to stricter regulatory requirements and the need for further evaluations, prompting the company to reallocate funds to a project with more immediate needs [7][8] - The "Integrase Inhibitor Drug Research and Clinical Study Project" is crucial for the company's pipeline, aiming to develop a new generation of integrase inhibitors for HIV treatment [9][10] Impact of Changes - The adjustments are expected to improve the efficiency of fund usage and support the company's long-term development strategy without adversely affecting normal operations [12][14] - The project aims to enhance the effectiveness and safety of HIV treatments, aligning with national policy goals and expanding the company's product offerings [10][12] Approval Process - The board of directors and the supervisory board have approved the changes, which will be submitted for shareholder approval [13][14]